Company Overview and News
It has become harder and harder to find good investment ideas that trade at reasonable multiples, have some decent upside potential, and also pay dividends. One sector that was on fire for most of last year, has been beaten down hard recently despite a plethora of positives in the group. The financials are offering growth investors the best entry points in years, and could be a leading sector the rest of 2018.
WFCNP C.WSA WFC.PRL WFC.PRJ WFC.PRT C.WS.B WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN C.WS.A C.PRP C.PRU WFC.PRY WFC.PRX WFC.PRW WFC.PRV C.PRS WFC WFC.WS C C.PRL PNC.PRP C.PRJ PNC.PRQ C.PRK PNCFO C.PRG C.PRC PNC.WS JPM C.PRPCL CGBBW PNC PNUCL
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DGLD GS.PRB MS.PRE GS.PRA MS.PRF MS.PRG MS.PRA CS GS GLSSP UGLD STI-A STI.PRE MS JBK STI.WS.B STI.WS.A DSLV VIIX GSC GS.PRICL CSSLF PNC.PRP VIIZ TFG PNC.PRQ PNCFO GSJ GS.PRJ GS.PRI CSGKF PNC.WS STI MS.PRI GS.PRD MS.PRK GS.PRC PNC PNUCL ZIV USLV TVIX GS.PRN GJS GS.PRK XIV
Global stock markets rebounded yesterday after political crises in Italy and Spain sent stocks into a tailspin. Unfortunately, for investors things could get worse from here.
PNC.WS PNC.PRP PNC PNC.PRQ PNUCL PNCFO
On May 28, we issued an updated research report on The PNC Financial Services Group (PNC - Free Report) . The company’s cost-containment efforts to drive operational efficiency along with steady loan and deposit growth indicate its upside potential. However, lack of loan diversification remains a concern.
HRL CMA.WS PNC.WS NTRS CMA PNC.PRP NTRSP PNC PNC.PRQ PNUCL PNCFO CMPWW
The days of increased regulatory scrutiny are over for U.S. financial stocks. The Congress approved a plan on May 22 to scale down stringent banking regulations or the Dodd-Franck act undertaken in the height of the 2008 financial crisis.
CBSH STT.PRC STT.PRE TCBI STT.PRD STT.PRG GDOT KRE STT SBNY SBNYW CBSHP PNC.PRP PNC.PRQ PNCFO TCBIL PACW UTX FFIN CBCB TCBIW PNC.WS TCBIP PNC PNUCL EWBC KBE
Main Street banks are feeling squeezed by competition from new rivals: nonbanks like hedge funds and private-equity firms that are elbowing into business loans.
RF.PRB STI.WS.B RF.PRA STI.WS.A PNC.PRP PNC.PRQ RF PNCFO FITBI PNC.WS STI STI-A PNC PNUCL STI.PRE FITB
Village Bank & Trust Financial Corp. (NASDAQ:VBFC) has 15 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 713,523 shares. Largest shareholders include Lehman Kenneth R, Pnc Financial Services Group, Inc., Banc Funds Co Llc, Minerva Advisors LLC, Geode Capital Management, Llc, River Oaks Capital LLC, UBS Group AG, Deutsche Bank Ag\, Morgan Stanley, and Bessemer Group Inc.
DB PNC.PRP PNC.PRQ MS.PRE CEI PNCFO MS.PRF MS.PRG ABEO MS.PRA PNC.WS MS.PRI UBS MS.PRK PNC PNUCL UBS.PRDCL VBFC MS ABEOW ULSGF
The nation's largest banks — and public companies, for that matter — are preparing for a timeout from the courtroom following years of being pummeled by shareholder and investor lawsuits in the wake of the Great Recession.
WFC WFCNP WFC.WS RF.PRB RF.PRA PNC.PRP PNC.PRQ WFC.PRL PNCFO RF WFC.PRJ WFC.PRT WFC.PRR PNC.WS WFC.PRQ WFC.PRP WFC.PRO WFC.PRN PNC PNUCL WFC.PRY WFC.PRX WFC.PRW WFC.PRV
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET